Muhammad is a Cancer Scientist, Interested in designing new therapeutic approach and technology-based platforms. His core expertise lies in gene and protein editing technologies, reverse-engineering, biological drug development, designing and executing translational experiments and protocol in cancer field. Besides, He founded KAHF Biotech, Inc., to open a new avenue for prevention and treatment of metastatic tumor cells.
As the CEO and Founder of KAHF Biotech, Inc., I am responsible for setting the strategic vision and guiding the company’s scientific and business direction. I lead efforts to secure funding, build key partnerships, and translate our innovative research into viable clinical solutions. My role involves making high-stakes decisions, aligning our team around clear goals, and fostering a mission-driven culture focused on advancing impactful therapies for pancreatic cancer and beyond.
His Areas of Expertise Are:
- Designing and developing CRISPR/Cas9 Technology for Knock-In, Knock-out, and Knock-down
- Designed and developed CRISPR/Cas13 and CRISPR Activation (SUNTAG) Systems
- Viral production (Lentivirus, Retrovirus, and Adeno Associated Virus)
- Designing short/small hairpin RNA (shRNA) for lentivirus
- Biotin Ligase or BioID Technology, a Tool for Protein-Proximity Labeling in Living Cells
- Degron Technology for discovering and validating new disease targets
- Different Molecular Cloning Techniques
- Electroporation, Transfection, and Transduction
- Orthotopic Tumor Model Development
- Novel Chimeric Antigen Receptor (CAR) Plasmids Development
- Expert in Recombinant Monoclonal Antibodies Development & Designing
- Expert in therapeutic Dicer Substrate siRNA Development & Designing
